October 17, 2008
Velcera Announces Voluntary Termination of Registration With the SEC |
June 30, 2008
Velcera Announces FDA Confirms VEL504 Clinical Program |
June 19, 2008
Velcera Appoints Sal Uglietta to Board of Directors |
June 9, 2008
Velcera Announces Completion of Enrollment in VEL502 Clinical Trial |
June 2, 2008
Velcera Announces Positive FDA Meeting on VEL504 Product |
April 24, 2008
Velcera Announces Initiation of Clinical Trial with VEL502 |
January 29 , 2008
Velcera Announces Results from Two Canine Allergy Studies |
November 15, 2007
Velcera Receives FDA Feedback on Innovative Canine Allergy Product |
November 5, 2007
Velcera to Present at 9th Annual Acumen BioFin Healthcare Conference |
October, 2007
Velcera SB-2 Registration Statement Declared Effective by SEC |
September 17, 2007
Velcera to Present at Maxim Group Growth Conference |
September 17, 2007
Audio Webcast of Dennis Steadman's Presentation at Maxim Conference |
September 17, 2007
PowerPoint Presentation from Dennis Steadman's Presentation at Maxim Conference [PDF file] |
August 1, 2007
Pivotal Trials of First Promist™ Veterinary Pharmaceutical Product |
July 9, 2007
Velcera Appoints Two New Members to Board of Directors |
June 7, 2007
Velcera Signs Global Licensing Agreement for First Promist™ Product |
May 9, 2007
Matthew C. Hill Named Velcera's Chief Financial Officer |
March 19, 2007
Velcera Inc. and Argenta Manufacturing Ltd. Sign Process Development Agreement |
March 6, 2007
Velcera Inc. Closes on $10 Million Financing and Becomes a Public Company |
October 12, 2006
Velcera Wins Global Animal Pharm Award |
September 21, 2006
Presentation at Three-Rivers Venture Fair |
May 3, 2006
Presentation at Kalamazoo Innovation Forum |
March 3, 2006
Velcera Pharmaceuticals Signs Research Agreement |
October 27, 2005
Kevin Vasquez Appointed to Board of Velcera Pharmaceuticals |
August 30, 2005
Acceptability Trials in Dogs and Cats |
June 28, 2005
Dr. Mark Heit Joins Velcera in Pharmacokinetics Research Role |
February 21, 2005
Successful Oral Transmucosal Delivery of a Potential Equine Product (VEL-502) |
January 21, 2005
Successful Oral Transmucosal Delivery of a Potential Canine Product (VEL-502) |
December 17, 2004
Successful Oral Transmucosal Delivery of a Potential Canine Behavioral Product (VEL-501) |
October 18, 2004
Dr. Anthony Benitz to Lead Velcera Research & Development |
July 7, 2004
Dr. David Petrick to Head Velcera Regulatory Affairs |
